An Unprecedented Set of New Clinical Trials Using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision Making and Patient Outcomes
TORONTO and LAS VEGAS, Oct. 17, 2022 /PRNewswire/ — MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that more than 2,000 new MolecuLight data patients at the Symposium on Advanced Wound Care (SAWC) Fall 2022. The data will be presented through a combination of seven clinical posters and three clinical talks and workshops. The international conference will be held October 13-16, 2022 in Las Vegas, Nevada and is one of the largest multidisciplinary gatherings of wound care professionals in the world.
“We are delighted to have our customers share the results of more than 2,000 patients obtained with the MolecuLight imaging platform this week at SAWC Fall,” said Anil Amlani, CEO of MolecuLight. “This volume of clinical testing is unprecedented for a wound imaging device and illustrates the significant utility that the MolecuLight i:X and DX devices are offering across the full range of care settings. I am especially proud of the dramatic improvement in clinical outcomes in vulnerable patient populations when clinicians use the MolecuLight devices.This includes the elderly and disabled population in long-term care and skilled nursing facility settings, as well as studies in which the MolecuLight was used in populations of patients with various skin pigmentations.”
“My organization serves the skilled nursing and long-term wound care industry in multiple states. The MolecuLight procedure is the standard of care for our wound care professionals because of the unmatched insights it provides to our decision-making said Martha R Kelso, CEO of Wound Care Plus, LLC. “I will present our real-world testing and documented results with the use of the MolecuLight in SAWC, including improvements in wound healing rates and reduction in antibiotic use. In addition, there was a marked reduction in patients with serious related complications. with infection (cellulitis, sepsis, osteomyelitis, or any wound-associated hospitalization) in particular, without increasing the use of systemic antibiotics The improvements in outcomes for this vulnerable population through the use of this imaging device are very impressive and highly necessary.”
A presentation on MolecuLight titled Closing the Gap on Racial Disparities in the Diagnosis of Chronic Wound Infections: The Worrying Trend Involving Skin Pigmentation and the Role of Fluorescence Imaging, by Jonathan Johnson, MD, MBA CWSP, Medical Director of Comprehensive Wound Care Services and Capital Aesthetic
The MolecuLight i:X and DX clinical presentations and posters at SAWC Fall 2022 are as follows:
a) CLINICAL PRESENTATIONS
b) POSTERS
In addition to clinical posters and presentations at SAWC Fall 2022, MolecuLight i i:X® and DX™ imaging devices will be available for demonstration at the MolecuLight booth
MolecuLight i:X® and DX™ are the only imaging devices for real-time detection of high bacterial load in wounds that are FDA cleared, CE and Health Canada approved. With unmatched clinical evidence including more than 60 peer-reviewed publications and 1,500 patients, they are used by leading wound care centers globally.
About MolecuLight Inc.
MolecuLight Inc. is a privately held medical imaging company that has developed and commercializes its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially launched devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provides portable point-of-care imaging devices to the global wound care market for the detection and real-time localization of elevated levels of bacteria in wounds and for digital measurement of wounds. MolecuLight procedures performed in the United States may benefit from an available reimbursement pathway that includes two CPT® codes for physician work to perform “fluorescence imaging to determine the presence, location, and load of bacteria” and facility payment for hospital outpatient department (HOPD) and ambulatory surgical center (ASC) through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with relevant unmet needs globally, such as food safety, consumer cosmetics and other key industrial markets.
For more information, contact:
Rob Sandler Director de Marketing MolecuLight Inc. T. 1.647.362.4684 rsandler@moleculight.com www.moleculight.com
Images:
Photo – https://mma.prnewswire.com/media/1920418/MolecuLight_2_000__Patients__Worth_of_New_MolecuLight_Data_to_be.jpg Photo – https://mma.prnewswire.com/media/1920419/MolecuLight_2_000__Patients__Worth_wire_beam_Newmedia._news.com/ 1920420/MolecuLight_2_000__Patients__Worth_of_New_MolecuLight_Data_to_be.jpg
View original content: https://www.prnewswire.com/news-releases/se-presentaran-nuevos-datos-de-moleculight-de-mas-de-2-000-pacientes-en-la-conferencia-sawc-fall-2022–301650441.html
